Christina Saldivar
Neurology · Austin, TXNPI 1114239241
Payments from drug & device makers
Across 118 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$421
- Genentech USA, Inc.$303
- Novartis$298
- Biogen$257
- Teva Pharmaceuticals USA, Inc.$125
- Lilly USA, LLC$119
- plus $837 from 20 others
What the payments were for
- Food & beverage$2,360100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $421 |
| Genentech USA, Inc. | 21 | $303 |
| Novartis | 15 | $298 |
| Biogen | 11 | $257 |
| Teva Pharmaceuticals USA, Inc. | 4 | $125 |
| Lilly USA, LLC | 5 | $119 |
| Pfizer | 6 | $110 |
| Neurocrine Biosciences, Inc. | 5 | $90 |
| Vanda Pharmaceuticals Inc. | 3 | $80 |
| TG Therapeutics, Inc. | 2 | $65 |
| Amneal Pharmaceuticals LLC | 3 | $64 |
| Acadia Pharmaceuticals Inc | 2 | $50 |
| EMD Serono, Inc. | 2 | $43 |
| Octapharma USA, Inc. | 2 | $40 |
| MDD US Operations, LLC | 2 | $35 |
| Ipsen Biopharmaceuticals, Inc | 1 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| AstraZeneca | 1 | $25 |
| Eisai Inc. | 1 | $24 |
| Avanir Pharmaceuticals, Inc. | 1 | $23 |
| Argenx US, Inc. | 1 | $23 |
| SK Life Science, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Intrabio Inc | 1 | $16 |
| UCB, Inc. | 1 | $15 |
How this compares
$2,360 in reported general payments places this provider in the 45th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Austin
- Esther MelamedAustin$593K
- Sami AboumatarAustin$593K
- Ann BassSan Antonio$12.3M
- Kandasami SenthilkumarBeaumont$7.6M
- Bharathy SundaramSherman$7.2M
- Bhupesh DiheniaLubbock$6.9M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- Elizabeth PeckhamRound Rock$5.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.